TY - JOUR
T1 - Nonsense mutations in the shelterin complex genes ACD and TERF2IP in familial melanoma
AU - Aoude, Lauren G.
AU - Pritchard, Antonia L.
AU - Robles-Espinoza, Carla Daniela
AU - Wadt, Karin
AU - Harland, Mark
AU - Choi, Jiyeon
AU - Gartside, Michael
AU - Quesada, Víctor
AU - Johansson, Peter
AU - Palmer, Jane M.
AU - Ramsay, Andrew J.
AU - Zhang, Xijun
AU - Jones, Kristine
AU - Symmons, Judith
AU - Holland, Elizabeth A.
AU - Schmid, Helen
AU - Bonazzi, Vanessa
AU - Woods, Susan
AU - Dutton-Regester, Ken
AU - Stark, Mitchell S.
AU - Snowden, Helen
AU - Van Doorn, Remco
AU - Montgomery, Grant W.
AU - Martin, Nicholas G.
AU - Keane, Thomas M.
AU - López-Otín, Carlos
AU - Gerdes, Anne Marie
AU - Olsson, Hakan
AU - Ingvar, Christian
AU - Borg, Ake
AU - Gruis, Nelleke A.
AU - Trent, Jeffrey M.
AU - Jönsson, Göran
AU - Bishop, D. Timothy
AU - Mann, Graham J.
AU - Newton-Bishop, Julia A.
AU - Brown, Kevin M.
AU - Adams, David J.
AU - Hayward, Nicholas K.
N1 - Funding Information:
LGA and KW are supported by PhD scholarships from the Australia and New Zealand Banking Group Limited Trustees and Rigshospitalet, University Hospital of Copenhagen, respectively. ALP is supported by Cure Cancer Australia. NKH and GWM are supported by fellowships from the National Health and Medical Research Council of Australia (NHMRC).DJA,CDRE,and TMK were supported by Cancer Research UK and the Wellcome Trust. CDRE was also supported by Consejo Nacional de Ciencia y Tecnología of Mexico. MH, JANB, and DTB were supported by Cancer Research UK. NAG and RvD were supported by a grant from the Dutch Cancer Society (UL 2012–5489). GJ, ÅB, HO, and CI were supported by the Swedish Research Council, the Swedish Cancer Society and the Nordic Cancer Union. HO was also supported by European Research Council. KMB and JC are supported by the Division of Cancer Epidemiology and Genetics, National Cancer Institute. CLO is an Investigator of the Botín Foundation, and work at his laboratory is supported by grants from the Spanish Ministry of Economy and Competitiveness and Red Temática de Investigación del Cáncer (RTICC). VQ is a Ramón y Cajal fellow supported by the Consolider-Ingenio RNAREG Consortium. The work was funded in part by the NHMRC, Cancer Institute NSW, Cancer Council Queensland, the Melanoma Research Alliance, and the Aase and Ejnar Danielsens fund.
Publisher Copyright:
© The Author 2014. Published by Oxford University Press. All rights reserved.
PY - 2015/2/1
Y1 - 2015/2/1
N2 - Background: The shelterin complex protects chromosomal ends by regulating how the telomerase complex interacts with telomeres. Following the recent finding in familial melanoma of inactivating germline mutations in POT1, encoding a member of the shelterin complex, we searched for mutations in the other five components of the shelterin complex in melanoma families. Methods: Next-generation sequencing techniques were used to screen 510 melanoma families (with unknown genetic etiology) and control cohorts for mutations in shelterin complex encoding genes: ACD, TERF2IP, TERF1, TERF2, and TINF 2. Maximum likelihood and LOD [logarithm (base 10) of odds] analyses were used. Mutation clustering was assessed with χ2 and Fisher's exact tests. P values under. 05 were considered statistically significant (one-tailed with Yates' correction). Results: Six families had mutations in ACD and four families carried TERF2IP variants, which included nonsense mutations in both genes (p.Q320X and p.R364X, respectively) and point mutations that cosegregated with melanoma. Of five distinct mutations in ACD, four clustered in the POT1 binding domain, including p.Q320X. This clustering of novel mutations in the POT1 binding domain of ACD was statistically higher (P =. 005) in melanoma probands compared with population control individuals (n = 6785), as were all novel and rare variants in both ACD (P =. 040) and TERF2IP (P =. 022). Families carrying ACD and TERF2IP mutations were also enriched with other cancer types, suggesting that these variants also predispose to a broader spectrum of cancers than just melanoma. Novel mutations were also observed in TERF1, TERF2, and TINF2, but these were not convincingly associated with melanoma. Conclusions: Our findings add to the growing support for telomere dysregulation as a key process associated with melanoma susceptibility.
AB - Background: The shelterin complex protects chromosomal ends by regulating how the telomerase complex interacts with telomeres. Following the recent finding in familial melanoma of inactivating germline mutations in POT1, encoding a member of the shelterin complex, we searched for mutations in the other five components of the shelterin complex in melanoma families. Methods: Next-generation sequencing techniques were used to screen 510 melanoma families (with unknown genetic etiology) and control cohorts for mutations in shelterin complex encoding genes: ACD, TERF2IP, TERF1, TERF2, and TINF 2. Maximum likelihood and LOD [logarithm (base 10) of odds] analyses were used. Mutation clustering was assessed with χ2 and Fisher's exact tests. P values under. 05 were considered statistically significant (one-tailed with Yates' correction). Results: Six families had mutations in ACD and four families carried TERF2IP variants, which included nonsense mutations in both genes (p.Q320X and p.R364X, respectively) and point mutations that cosegregated with melanoma. Of five distinct mutations in ACD, four clustered in the POT1 binding domain, including p.Q320X. This clustering of novel mutations in the POT1 binding domain of ACD was statistically higher (P =. 005) in melanoma probands compared with population control individuals (n = 6785), as were all novel and rare variants in both ACD (P =. 040) and TERF2IP (P =. 022). Families carrying ACD and TERF2IP mutations were also enriched with other cancer types, suggesting that these variants also predispose to a broader spectrum of cancers than just melanoma. Novel mutations were also observed in TERF1, TERF2, and TINF2, but these were not convincingly associated with melanoma. Conclusions: Our findings add to the growing support for telomere dysregulation as a key process associated with melanoma susceptibility.
UR - http://www.scopus.com/inward/record.url?scp=84925547048&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84925547048&partnerID=8YFLogxK
U2 - 10.1093/jnci/dju408
DO - 10.1093/jnci/dju408
M3 - Article
C2 - 25505254
AN - SCOPUS:84925547048
SN - 0027-8874
VL - 107
JO - Journal of the National Cancer Institute
JF - Journal of the National Cancer Institute
IS - 2
ER -